ClinicalTrials.gg
CompletedNCT05638347Updated Apr 21, 2023

A Trial of HRS-7085 Tablet in Healthy Participants With and Without Food Effect.

A Phase 1 interventional study of HRS-7085 tablets and Placebo tablet in Inflammatory Bowel Disease, sponsored by Atridia Pty Ltd.. Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-21.

Sponsored by Atridia Pty Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies in Inflammatory Bowel Diseases with a site in Australia — 11 open to participants now, 13 under way, 3 of them phase 3. Inflammatory Bowel Diseases · Australia.

Enrollment
48th of 49
16 · median 139
Started
2022
with 3 others
Phase 1
7 of 54
2 open now
Registered
41st of 54
by date

Among the 54 studies in Inflammatory Bowel Diseases with a site in Australia, this one is the 48th largest by enrollment of the 49 interventional ones that give a count, is one of 4 that started in 2022, is one of 7 in phase 1, and was the 41st registered.

Inflammatory Bowel Diseases

1,550 studies on the registry are indexed under Inflammatory Bowel Diseases; 423 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

11 of the 54 studies in Inflammatory Bowel Diseases with a site in Australia are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 133 (48%) set no upper age limit and 116 (42%) stop at 75 or younger; 76 take children under 18; 61 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Inflammatory Bowel Diseases with a site in Australia, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of HRS-7085.

03

Conditions studied

  • Inflammatory Bowel Disease
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to understand the trial procedures and possible adverse events, volunteers to participate in the trial.
  2. Male or female aged between 18 years and 55 years (inclusive) at the date of signed consent form.
  3. Total body weight 45 kg\~100 kg (inclusive) at screening, and (BMI) between 18 and 32 kg/m2 (inclusive).
  4. For healthy subjects, no abnormalities.
  5. Men and women of (WOCBP) must agree to take effective methods

Exclusion criteria

Exclusion Criteria:

  1. Known medical history of severe disease in cardiovascular, liver, kidney, digestive tract, mental nerve, hematology, metabolic disorders, etc.
  2. Severe injuries or major surgeries within 3 months before dosing.
  3. Subjects with infectious disease.
  4. Live/attenuated vaccine within 3 months prior to dosing or any vaccine during the trial.
  5. Blood donation or loss of ≥ 200 mL of blood within 1 month prior to dosing, or ≥ 400 mL of blood within 3 months prior to dosing; or receive a blood transfusion within 2 months prior to dosing.
  6. abnormalities in 12-Lead
  7. More than 5 cigarettes daily (or products with equivalent amount of nicotine) for 3 months prior to screening, or positive cotinine test at screening or baseline.
  8. Positive urine drug at screening or baseline.
  9. Subject who cannot perform venous blood sampling.
  10. Known history or suspected of being allergic to the study drugs and their .
  11. Use of prescription medicine within 2 weeks, or OTC medicine, within 1-week or 5 half-lives prior to dosing.
  12. History of alcohol abuse within 3 months prior to screening, or positive alcohol breath test at screening or baseline.
  13. Participation in clinical trials of other drugs or medical devices within 1 month or 5 half-lives prior to dosing.
  14. Special dietary requirements that cannot follow the meal plan in the food effect study.
  15. In the investigator's judgment, may increase the risk to the subject.
  16. Unwilling or unable to comply with the Lifestyle Guidelines detailed in this protocol.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    HRS-7085 tablets Cohort 1

    Part 1- HRS-7085 tablets

    Drug: HRS-7085 tablets · Drug: Placebo tablet

  • Experimental
    HRS-7085 tablets Cohort 6

    Part 1- HRS-7085 tablets

    Drug: HRS-7085 tablets · Drug: Placebo tablet

Interventions

  • Single oral administration

  • DrugPlacebo tablet

    Single oral administration

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events

    Time frame: Start of Treatment to end of study approximately 1 week

Secondary outcomes

  1. Pharmacokinetics-AUC0-last

    Area under the concentration-time curve from time 0 to last time point after HRS-7085 administration

    Time frame: Start of Treatment to end of study (approximately 1 week)

  2. Pharmacokinetics-AUC0-inf

    Area under the concentration-time curve from time 0 to infinity after HRS-7085 administration

    Time frame: Start of Treatment to end of study (approximately 1 week)

  3. Pharmacokinetics-Tmax

    Time to Cmax of HRS-7085

    Time frame: Start of Treatment to end of study (approximately 1 week)

  4. Pharmacokinetics-Cmax

    Maximum observed concentration of HRS-7085

    Time frame: Time Frame: Start of Treatment to end of study (approximately 1 week)

  5. Pharmacokinetics-CL/F

    Apparent clearance of HRS-7085

    Time frame: Time Frame: Start of Treatment to end of study (approximately 1 week)

  6. Pharmacokinetics-Vz/F

    Apparent volume of distribution during terminal phase of HRS-7085

    Time frame: Time Frame: Start of Treatment to end of study (approximately 1 week)

  7. Pharmacokinetics-t1/2

    Terminal elimination half-life of HRS-7085

    Time frame: Time Frame: Start of Treatment to end of study (approximately 1 week)

07

Study locations

1 site
  • Linear Clinical Research
    Nedlands, Western Australia 6009, Australia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Mar 2023, 3 months.

Of 35 industry-sponsored phase 1 interventional studies under Inflammatory Bowel Diseases, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's 3 months is below that.

Counting every sponsor, half of 51 studies reached it within 12 months; a quarter within 4 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2022
First posted
Dec 6, 2022
StartActual
Dec 5, 2022
Primary completionActual
Mar 16, 2023
CompletionActual
Mar 16, 2023
Last update
Apr 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05638347
Lead sponsor
Atridia Pty Ltd.
Responsible party
Sponsor
First posted
Dec 6, 2022
Start date
Dec 5, 2022
Primary completion
Mar 16, 2023
Completion
Mar 16, 2023
Last update
Apr 21, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-7085

Start the discussion